

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of Earliest Event Reported): August 16, 2021

CATALYST PHARMACEUTICALS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware
(State or other jurisdiction
of incorporation)

001-33057
(Commission
File Number)

76-0837053
(I.R.S. Employer
Identification No.)

**355 Alhambra Circle
Suite 801
Coral Gables, Florida**
(Address of principal executive offices)

33134
(Zip Code)

Registrant's telephone number, including area code: (305) 420-3200

Not Applicable

Former Name or Former address, if changed since last report

Securities registered pursuant to Section 12(b) of the Act:

| Title of Each Class | Name of Exchange on Which Registered | Ticker Symbol |
|--|---|------------------|
| Common Stock, par value \$0.001 per share | NASDAQ Capital Market | CPRX |

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events

On August 16, 2021, the Company issued a press release announcing that Mary Coleman has been appointed to the newly created position of Vice President, Head of Investor Relations. A copy of the Company's press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 [Press release issued by the Company on August 16, 2021.](#)

104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceuticals, Inc.

By: /s/ Alicia Grande

Alicia Grande

Vice President, Treasurer and CFO

Dated: August 16, 2021



Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations

CORAL GABLES, Fla., August 16, 2021 (GLOBE NEWSWIRE) – Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that Mary Coleman has been appointed to the newly created position of Vice President, Head of Investor Relations. This position will report to the Chief Executive Officer of Catalyst.

“We are delighted to welcome Ms. Coleman to the Catalyst team. Her extensive investor relations experience in the pharmaceutical industry and insights make her uniquely qualified to support our investor relations objectives,” said Patrick J. McEnany, Chairman and CEO of Catalyst. “In this newly created position, Ms. Coleman will play an instrumental role in developing and implementing our investor relations program as we continue to execute our growth strategy and elevate our profile among the investment community.”

Ms. Coleman added, “I am excited to join the Catalyst team, which has a profound commitment to developing novel medicines that address important needs for those patients living with rare diseases. I look forward to working with the team on communicating Catalyst’s growth strategy and enhance its profile to help deliver long-term value for shareholders.”

Ms. Coleman joins Catalyst with more than 20 years of investor relations and corporate communications experience in the biotechnology and specialty pharmaceutical industry. Ms. Coleman has held senior investor relations leadership positions with various publicly traded companies from early-stage to commercial-stage, leading the development and execution of the investor relations strategy to broaden and strengthen relationships with the investment community. She recently served as Vice President, Investor Relations at BioXcel Therapeutics and previously held the position of Head of Investor Relations at Jubilant Pharmaceuticals, Ltd., a global integrated pharmaceutical company where she served as a member of the company’s leadership team. Ms. Coleman received a B.A. degree from Bowling Green State University.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst’s New Drug Application for Firdapse® (amifampridine) Tablets 10 mg for the treatment of adults with LEMS was approved in 2018 by the U.S. Food & Drug Administration (“FDA”), and Firdapse® is commercially available in the United States. Further, Canada’s national healthcare regulatory agency, Health Canada, approved the use of Firdapse® for the treatment of adult patients in Canada with LEMS.

Firdapse® is currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2020 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Media Contact

David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com

Company Contact

Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com

###